Fracture incidence during teriparatide treatment (0 to < 18 months) and after teriparatide was discontinued [(18 to < 36 months) in glucocorticoid (GC) users and nonusers (total study cohort)]. The shaded section covers the period from 18 to < 36 months’ followup when teriparatide had been discontinued and the majority of patients were receiving other osteoporosis medications.
| Time Period, mo | N* (missing/unknown) | No. Fractures/10,000 pt-yrs | Total No. Fractures | Patients with ≥ 1 Fracture, n (%)** | Odds of Fracture*** (95% CI) | OR***† (95% CI) | p |
|---|---|---|---|---|---|---|---|
| GC users | |||||||
| 0 to < 6 | 294 (0) | 1272 | 18 | 15 (5.1) | 0.046 (0.027, 0.079) | — | — |
| 6 to < 12 | 269 (0) | 1608 | 21 | 17 (6.3) | 0.058 (0.034, 0.097) | 1.26 (0.66, 2.39) | 0.480 |
| 12 to < 18 | 249 (0) | 1150 | 14 | 13 (5.2) | 0.047 (0.027, 0.083) | 1.03 (0.48, 2.19) | 0.938 |
| 18 to < 24 | 231 (0) | 1211 | 13 | 12 (5.2) | 0.047 (0.026, 0.086) | 1.03 (0.46, 2.29) | 0.949 |
| 24 to < 30 | 204 (0) | 213 | 2 | 2 (1.0) | 0.009 (0.002, 0.034) | 0.19 (0.04, 0.83) | 0.028 |
| 30 to < 36 | 179 (0) | 120 | 1 | 1 (0.6) | 0.005 (0.001, 0.003) | 0.11 (0.01, 0.79) | 0.028 |
| Total | 294 (0) | 69 | 49 (16.7) | ||||
| GC nonusers | |||||||
| 0 to < 6 | 1287 (5) | 1085 | 68 | 61 (4.7) | 0.043 (0.033, 0.057) | — | — |
| 6 to < 12 | 1206 (2) | 637 | 37 | 34 (2.8) | 0.025 (0.018, 0.036) | 0.58 (0.38, 0.88) | 0.012 |
| 12 to < 18 | 1122 (1) | 533 | 29 | 28 (2.5) | 0.022 (0.015, 0.033) | 0.51 (0.32, 0.81) | 0.004 |
| 18 to < 24 | 1040 (2) | 473 | 23 | 22 (2.1) | 0.019 (0.012, 0.030) | 0.44 (0.27, 0.72) | 0.001 |
| 24 to < 30 | 905 (4) | 426 | 18 | 16 (1.8) | 0.016 (0.010, 0.026) | 0.37 (0.21, 0.64) | < 0.001 |
| 30 to < 36 | 812 (0) | 373 | 14 | 12 (1.5) | 0.013 (0.007, 0.024) | 0.30 (0.16, 0.56) | < 0.001 |
| Total | 1287 (5) | 189 | 159 (12.4) |
↵* Number of patients included in the observation (number of patients with fracture data missing or unknown at this observation).
↵** As some patients experienced a fracture more than 1 time period, the total was not the sum of patients with a fracture in each period.
↵*** Model adjusted by age, prior bisphosphonate use, and fracture in last 12 months before starting teriparatide.
↵† Compared with 0 to < 6-month period.